Rajesh Krishna 博士是 Certara 战略咨询部门的一体化药物开发高级总监。在加入 Certara 之前，Rajesh 曾就职于默克、赛诺菲（即原来的安万特）和百时美施贵宝 (Bristol-Myers Squibb)，从事转化和临床开发方面，拥有超过 20 年的制药行业经验。He has contributed to 40+ INDs, more than 200 Phase 1/1b studies; and to the worldwide registration of 9 new molecular entities. -- David Gutstein, MD is a vice president at Regeneron with keen interest and specialization in gene-based therapeutics and is a guest contributor to this blog. Dr Gutstein’s research includes the Regeneron collaboration with Intellia in gene editing focusing on NTLA-2001 and other programs.
© 2025 Certara. 保留所有权力。 | 隐私政策
